Functional expression of chimeric receptor genes in human T cells

2001/02/01 by Zelig Eshhar, Tova Waks, Alain Bendavid +2 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #CAR-T cell therapy research #Viral Infectious Diseases and Gene Expression in Insects #Virus-based gene therapy research

paper · doi:10.1016/s0022-1759(00)00343-4

Citations

• Antigen‐specific targeting of CD28‐mediated T cell co‐stimulation using chimeric single‐chain antibody variable fragment‐CD28 receptors
• Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Cited by

• In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI. [europepmc]
• Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. [europepmc]
• Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. [europepmc]
• Genetic engineering of T cells for adoptive immunotherapy. [europepmc]
• Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. [europepmc]
• 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. [europepmc]
• Designing customized cell signalling circuits. [europepmc]
• Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. [europepmc]
• Adoptive cell therapies for glioblastoma. [europepmc]
• Chimeric antigen receptor therapy for cancer. [europepmc]
• Engineered T cells for cancer therapy. [europepmc]
• Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. [europepmc]
• Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. [europepmc]
• The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies. [europepmc]
• Immune engineering: from systems immunology to engineering immunity. [europepmc]
• From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance. [europepmc]
• Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells. [europepmc]
• Opportunities and Challenges for Antibodies against Intracellular Antigens. [europepmc]
• Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies. [europepmc]
• Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. [europepmc]
• Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance. [europepmc]
• Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. [europepmc]
• Application of mRNA Technology in Cancer Therapeutics. [europepmc]
• Engineering chimeric antigen receptor T cells for solid tumour therapy. [europepmc]
• Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. [europepmc]